ABSTRACT. Thyrotropin releasing hormone (TRH) readily crosses the placenta and stimulates the fetal pituitary. We studied the response of the maternal and fetal pituitarythyroid axes to TRH and the influence of prenatal exposure to TRH on the physiological postnatal increase in thyrotropin (TSH) and triiodothyronine (T 3 ) in the neonate. Twenty-six pregnant women received TRH (400 or 600 ILg) intravenous or saline (controls) either 2 or 12 h before elective cesarean section at term. Administration of 400 ILg of TRH resulted in significant elevations of maternal TSH (15.7 ± 2.9 versus 3.2 ± O.4ILU/ml,p < 0.01) and prolactin (416 ± 94 versus 223 ± 41 nglml, p < 0.05) 2 h later.
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Maternal T 3 remained unchanged. A higher dose of TRH (600 ILg) produced comparable results. Maternal administration of TRH (400 ILg) 2 h before delivery resulted in significant increases in fetal TSH and T 3 over controls (21.1 ± 3.7 versus 4.8 ± 1.0 ILU/ml, and 132 ± 12 versus 64 ± 9 ngldl, p < 0.01, respectively). Cord blood hormone levels 12 hours after TRH administration were similar to controls. Higher doses of TRH did not produce further increases in fetal TSH or T 3 • Control and treated neonates demonstrated similar physiological postnatal increases in TSH and T3, suggesting that prior exposure to TRH did not blunt this response. These data suggest that maternal administration of TRH is an effective way of increasing fetal T 3 levels, and that this treatment does not inhibit the postnatal surge in TSH and T 3 • (Pediatr Res 20: 982-986, 1986) effective so that delivery of the infant often takes place before any beneficial effect can occur (3) . In addition, g1ucocorticoids may be less effective in very immature and in male fetuses (2-5). Several investigators have proposed the use of thyroid hormones to enhance fetal lung maturation but results with this approach have been less favorable than those observed with g1ucocorticoids (6) (7) (8) . Since there is little transplacental passage ofT3, T4, or TSH (9-11), these studies have involved intraamniotic administration of thyroid hormones.
Recent evidence suggests that g1ucocorticoids and thyroid hormones acts synergistically to enhance fetal lung maturation (12) (13) (14) . The combined hormone regimen also induces a more rapid acceleration of surfactant production in human fetal lung in culture than steroids alone (IS). For these reasons, the use of combined hormonal treatment with g1ucocorticoids and thyroid hormones to enhance fetal lung maturation has been proposed (14, 15) . Such treatment could involve the use of TRH, which, unlike thyroid hormones, crosses the placenta readily and evokes secretion of fetal TSH, T 3 , and T 4 in humans and laboratory animals (16) (17) (18) . TRH alone also has been shown to increase surfactant secretion in fetal rabbits (19) .
In anticipation of the clinical use of TRH to induce fetal lung maturation, we conducted a pilot study to determine the timing and extent of the maternal and fetal responses to TRH and the influence offetal exposure to TRH on the normal postnatal surge in TSH and thyroid hormone levels (20, 21) .
MATERIALS AND METHODS
Normal pregnant women about to undergo elective cesarean section at term at the Hospital Sotero del Rio, Chile, were eligible for the study. After obtaining consent, one group of women was injected intravenously with either one ml of normal saline, the diluent in the TRH preparation (controls, n = 6), TRH (Thypinone, Abbott Laboratories, North Chicago, IL) 400 ILg (n = 8), or TRH 600 ILg (n = 5), 2 h before delivery. Another group of women was injected with 400 ILg of TRH twelve hours before delivery by cesarean section (n = 7). After the intravenous injection, the maternal vital signs were monitored closely. Uterine contractility and fetal heart rate (Corometrics, Wallingford, CT). were continuously monitored in most instances until the time ofthe cesarean section. Immediately after delivery, a sample of arterial blood from the umbilical cord was obtained for determination of blood gases and glucose.
Hormonal determinations. Samples of blood were drawn from the mothers just before the intravenous injection of saline or TRH, and at 30 and 120 min thereafter. Cord blood was collected at the time of delivery. Samples of 1.5 ml of venous blood from the neonates were obtained at I, 2, and 6 h after birth and the 982 A total of 26 pregnant women at tenn and their newborns was studied. As shown in Table I , there were no differences in gestational age and birth weight among the groups. All infants had Apgar scores above 7 at I and 5 min after birth. The umbilical arterial blood gas values and glucose concentrations in cord blood were not different in the various groups. After slow intravenous injection of TRH no increases in maternal blood pressure were observed, nor were abnonnalities of uterine contractility or fetal heart rate noted.
Maternal response to TRH. The changes observed in the maternal serum levels ofTSH, T 3 , and PRL, after administration of TRH are shown in Table 2 . There were significant increases Group/Time of TSH T) Prolactin exposure n (JlU/ml) (ngfdl) (ng/ml) DISCUSSION Thyrotropin-releasing honnone stimulates TSH and PRL release by the pituitary in a dose-dependent fashion (23, 24) . Maximal increases in serum TSH are observed after intravenous injection of 400-500 JoLg ofTRH to nonnal humans of both sexes (24) . Administration of TRH to pregnant women, in doses betwen 200-500 JoLg, have been reported to result in a severalfold increase in maternal serum TSH levels and a less marked rise in serum PRL concentrations (25) (26) (27) . These observations were confinned in our study where injection of 400 JoLg of TRH resulted in approximately a 5-fold increase in maternal serum TSH levels and a doubling of serum PRL levels. When doses of 600 JoLg of TRH were administered, no further stimulation was observed. These findings suggest that the maximal response to TRH is not significantly altered during pregnancy.
Maternal serum T 3 levels increase during gestation and rise even further during labor in humans and nonhuman primates (16, 17, 28) . Azukizawa et al. (16) reported that 2 h after * Statistically significant difference from control values, P < 0.0 I by analysis of variance and Student-Newman-Keuls test. Table 3 . In the control group, the mean fetal serum TSH level was significantly higher than the corresponding maternal level (4.8 ± 1.0 vs 2.2 ± 0.2 JoLU/ml, p < 0.05).
Conversely, the mean fetal serum T 3 level was lower in the fetuses than in their mothers (64.7 ± 9.4 versus 195.8 ± 19.3 ng/ dl, p < 0.0 I). Maternal administration of 400 JoLg of TRH 2 h prior to delivery resulted in a 4-fold increase in fetal TSH levels above control values (21.1 ± 3.7 versus 4.8 ± 1.0 JoLV/ml, p < 0.01). Fetal T 3 levels 2 h after TRH administration also were significantly elevated when compared to controls (132.5 ± 12.6 versus 64.7 ± 9.4 ng/dl, p < 0.01). Although the mean fetal PRL level was higher in treated fetuses, this difference was not statistically significant. Maternal administration of 600 JoLg of TRH 2 h prior to delivery produced similar results. When 400 JoLg of TRH were administered to the mother 12 h prior to delivery, no elevation of cord blood TSH, T 3 , or PRL was detected (Table 3) .
In addition, two women in premature labor between 32 and 33 wk of gestation were given 400 JoLg of TRH 2 to 3 h prior to delivery. The cord blood TSH levels were 34 and 27 JoLV/ml and the T 3 1evels were 108 and 115 ng/dl, respectively. These values are similar to those obtained in TRH-treated full term infants. There was also a further increase ofTSH and T 3 after birth.
Postnatal changes oj TSH and T 3 •
The postnatal changes in the serum levels ofTSH and T 3 in infants born to mothers given saline or TRH 2 or 12 h prior to delivery are shown in Figures  1 and 2 .
All infants exhibited the physiological increase in TSH and T 3 levels after birth, but there were no significant differences in these levels among the various groups at 1, 2, or 6 h after birth. given 2 h prior to delivery, and those exposed to TRH 400 f.l.g given 12 h prior to delivery (0). * p < 0.01 by ANOYA and Student-Newman-Keuls test.
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(ng/dl) Postnatal changes in serum T) levels in control infants (0), in those exposed to TRH 400 f.l.g (l:» or 600 f.l.g (0) given 2 h prior to delivery, and those exposed to TRH 400 f.l.g given 12 h prior to delivery (0). * p < 0.01 by ANOYA and Student-Newman-Keuls test.
administration of TRH to preterm pregnant rhesus monkeys, there was an increase of about 50% in serum T) levels. This increase was more pronounced in nonpregnant rhesus monkeys. More recently, however, Miyamoto (27) reported a failure to observe changes in serum T 3 levels 30 and 90 min after the administration of 500 /Lg of TRH to pregnant women at term. Our data are consistent with the latter observation in that we found no change in maternal serum T 3 2 h after administering doses ofTRH that maximal1y stimulate the pituitary. Pregnancy can alter the response ofthe pituitary to stimulation with TRH. For instance, the relative increase in PRL after TRH administration is relatively lower during pregnancy, whereas the TSH response is largely unchanged (25) . Whether the response ofthe maternal thyroid to TRH-induced TSH secretion decreases at term when maternal serum T3 levels are considerably higher than in early pregnancy is unclear (28) . Also it is possible that in Our study a hemodilution effect secondary to fluid administration before epidural anesthesia for cesarean section might have obscured small increases in serum T3 levels after the TRH injection.
Mild short-term side effects of the administration of TRH to pregnant women and normal controls have been reported (24, 25) . They include nausea, desire to void, and small changes in blood pressure. In a study involving pregnant rhesus monkeys, increased uterine contractility was observed in one of eight animals after infusion ofTRH (16) . Other studies, however, have not reported any side effects in either mother or fetus (26, 27) . In our study, no maternal or fetal side effects were observed.
Many authors have shown that the placenta is relatively impermeable to TSH and thyroid hormones, and that significant maternal/fetal gradients ofthese hormones exist; the serum TSH levels are lower and the serum T3 levels are higher in the mother as compared to the fetus (16, 17, 27, 29, 30) . Our results are in agreement with these previous findings. Administration of large amounts of T3 or T4 to the mother is necessary in order to increase the fetal levels of these hormones, as less than 5% of the amount given crosses the placenta (9, 10, 13, 17) . This can be partially explained by the active placental conversion of T 4 to reverse T 3 , and T 3 to 3,3' diiodothyronine, mediated by a placental inner ring iodothyronine deiodinase (31, 32) . Intraamniotic injection of thyroid hormones, however, does result in higher fetal levels (33) . TRH, on the other hand, crosses the placenta readily and stimulates the fetal pituitary (16) (17) (18) .
Azukizawa et at. (16) and Melmed et at. (17) administered a bolus of TRH to the pregnant rhesus monkey before term, and demonstrated that the fetus had a greater increase in serum TSH and T 3 levels than the mother. TRH-induced PRL release, however, was more pronounced in the mother. We observed as-fold increase in maternal serum TSH levels 30 min after TRH infusion, followed by a decrease to levels two to three times the baseline values 90 min later. The PRL response was less pronounced and of short duration. The fetal serum TSH, however, was still markedly elevated 2 h after maternal administration of TRH, and fetal serum T3 levels at this time were also significantly elevated when compared to control values. Fetal serum PRL levels were slightly higher than control levels but did not reach statistical significance. It is possible that the fetal PRL levels were elevated prior to delivery, as the PRL levels peak at 30-60 min after TRH administration.
Roti et at. (18) also found that maternal administration of TRH resulted in peak fetal serum TSH values 40-60 min after the infusion; thereafter serum TSH showed a steady decline. Maximal stimulation of the fetal thyroid occurred about 2 h after the maternal injection of TRH. In this study, the increase of maternal TSH levels induced by TRH administration was less pronounced than that observed in the fetuses. Therefore the authors concluded that the fetal pituitary was more sensitive to TRH than its maternal counterpart. Many factors may contribute to the more marked response of the fetal pituitary-thyroid axis to TRH. Accumulation ofTSH in the pituitary gland of the fetus has been observed late in gestation (30) , and the TRHinduced TSH surge is less suppressible by T3 in the fetus (17) . Besides the increased responsiveness of the fetal pituitary, a lower level ofTRH-degrading activity, may allow for a more sustained pituitary stimulation (34) .
A marked increase in serum TSH, PRL, and T3 levels normally occurs soon after delivery in full-term neonates (20, 30) . Preterm infants also exhibit a postnatal increase in serum TSH and T3 levels, but it can be less marked than that of term neonates, particularly in those infants who develop RDS (21, 35) . At least part of this response seems to be due to an increase in TRH, but the response also is related to neonatal cooling and cutting of the umbilical cord (30, 36) . In addition, the postnatal increase in serum T3 levels can be only partly accounted for by increased secretion; it may also reflect increased peripheral conversion of T4 to T 3 instead of reverse T 3 (37) . In our study, the postnatal increase in TSH and T 3 occurred in control infants and in those exposed to TRH 2 or 12 h prior to delivery. The 1 h levels of these hormones were similar in the treated and control groups despite the fact that the cord-blood values of both TSH and T3 were significantly higher in the TRH-treated patients. Thus, prenatal administration of TRH does not seem to suppress the physiological postnatal response of the pituitary-thyroid axis. Intraamniotic administration of T 4 , however, can reduce the postnatal surge of TSH (33) .
Evidence supporting a faster and more marked acceleration of fetal lung maturation by the combination of glucocorticoids and thyroid hormones as opposed to glucocorticoids alone has accumulated recently (12) (13) (14) (15) . Liggins el at. (38) have shown that there is a more profound enhancement of fetal lung maturation in lambs exposed to a combination of glucocorticoids, T 3 , and PRL than when only one or two of these hormones are used. Maternal administration of TRH at term results in fetal serum T3 levels that approximate the concentrations required to stimulate surfactant synthesis in fetal-human lung in organ culture (15) . Premature monkey fetuses and preterm infants also respond to TRH with increases in serum TSH and T3 to levels that may enhance lung maturation (16, 17, 38, 39) . Even higher fetal T 3 levels may result from the concomitant use of glucocorticoids and TRH (40) .
Since administration ofTRH during pregnancy does not seem to result in significant side effects in the mother or fetus, or in suppression of the postnatal surge ofTSH and thyroid hormones, this therapy may be useful clinically to accelerate fetal lung maturation. Enhanced surfactant secretion already has been demonstrated in fetuses of pregnant rabbits injected with TRH (19) . Whether maternal administration of TRH, alone or in combination with glucocorticoids, will be more effective for the prevention of RDS than current glucocorticoid therapy remains to be investigated.
